Greenwich LifeSciences (Nasdaq: GLSI) is a public clinical-stage biopharmaceutical company focused on the development of an immunotherapy to prevent breast cancer recurrences in …

Greenwich LifeSciences, Inc. (Nasdaq: GLSI) is a clinical-stage public biopharmaceutical company based in the Houston, TX area that is developing GP2, a novel peptide …

Jan 29, 2025 · Company Profile Business Description: Greenwich LifeSciences (the “Company”) is a clinical-stage biopharmaceutical company focused on the development of GP2, an …

Greenwich LifeSciences, Inc., a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers.

Jan 30, 2025 · GLSI | Complete Greenwich LifeSciences Inc. stock news by MarketWatch. View real-time stock prices and stock quotes for a full financial overview.

The Greenwich LifeSciences’ leadership is dedicated to discovering and developing biotherapeutics that advance patient care.

Business Description: Greenwich LifeSciences (the “Company”) is a clinical-stage biopharmaceutical company focused on the development of GP2, an immunotherapy to …

Feb 14, 2024 · Greenwich LifeSciences is a clinical-stage biopharmaceutical company focused on the development of GP2, an immunotherapy to prevent breast cancer recurrences in patients …

Jan 22, 2025 · Greenwich LifeSciences, Inc. announced progress in the commercial manufacturing of GP2, an immunotherapy for preventing breast cancer recurrences, alongside …

Greenwich LifeScience’s GP2 immunotherapy is a HER2-derived peptide which targets HER2-expressing tumor cells.